Literature DB >> 17211452

Differences between the abilities of tegaserod and motilin receptor agonists to stimulate gastric motility in vitro.

E M Jarvie1, V J North Laidler, S Corcoran, A Bassil, G J Sanger.   

Abstract

BACKGROUND AND
PURPOSE: Motilin or 5-HT4 receptor agonists stimulate gastrointestinal motility. Differences in activity are suggested but direct comparisons are few. A method was devised to directly compare the gastric prokinetic activities of motilin, the motilin receptor agonist, erythromycin, and the 5-HT4 receptor agonist, tegaserod. EXPERIMENTAL APPROACH: Gastric prokinetic-like activity was assessed by measuring the ability to facilitate cholinergically-mediated contractions evoked by electrical field stimulation (EFS) in rabbit isolated stomach. Comparisons were made between potency, maximal activity and duration of responses. KEY
RESULTS: Rabbit motilin (r.motilin) 0.003-0.3 microM, [Nle13]motilin 0.003-0.3 microM, erythromycin 0.3-10 microM and tegaserod 0.1-10 microM caused concentration - dependent potentiation of EFS-evoked contractions. The potency ranking was r.motilin = [Nle13]motilin > tegaserod > erythromycin. The Emax ranking was r.motilin = [Nle13]motilin = erythromycin > tegaserod. Responses to r.motilin and [Nle13]motilin faded rapidly (t1/2 9 and 11 min, respectively) whereas those to erythromycin and tegaserod were maintained longer (t1/2 24 and 28 min). The difference did not appear to be due to peptide degradation. A second application of [Nle13]motilin was excitatory after 60 min contact and fade of the initial response (responses to 0.03 and 0.1 microM [Nle13]motilin were not different from those caused by the first application). CONCLUSIONS AND IMPLICATIONS: Prokinetic-like activities of the 5-HT4 agonist tegaserod and the motilin receptor agonists were compared by measuring changes in cholinergically-mediated contractions. This novel approach highlighted important differences between classes (greater Emax of motilin, compared with tegaserod) and for the first time, within each class (short t1/2 for motilin, compared with erythromycin).

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17211452      PMCID: PMC2189716          DOI: 10.1038/sj.bjp.0707118

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  37 in total

1.  Prokinetics in patients with gastroparesis: a systematic analysis.

Authors:  A Sturm; G Holtmann; H Goebell; G Gerken
Journal:  Digestion       Date:  1999 Sep-Oct       Impact factor: 3.216

2.  The use of long-term, low-dose erythromycin in treating persistent gastric stasis.

Authors:  Alice Hunter; Claud Regnard; Christine Armstrong
Journal:  J Pain Symptom Manage       Date:  2005-05       Impact factor: 3.612

3.  Effect of atilmotin on gastrointestinal transit in healthy subjects: a randomized, placebo-controlled study.

Authors:  M-I Park; I Ferber; M Camilleri; K Allenby; R Trillo; D Burton; A R Zinsmeister
Journal:  Neurogastroenterol Motil       Date:  2006-01       Impact factor: 3.598

4.  Involvement of two different pathways in the motor effects of erythromycin on the gastric antrum in humans.

Authors:  B Coulie; J Tack; T Peeters; J Janssens
Journal:  Gut       Date:  1998-09       Impact factor: 23.059

Review 5.  Tegaserod.

Authors:  L J Scott; C M Perry
Journal:  Drugs       Date:  1999-09       Impact factor: 9.546

6.  Receptor for motilin identified in the human gastrointestinal system.

Authors:  S D Feighner; C P Tan; K K McKee; O C Palyha; D L Hreniuk; S S Pong; C P Austin; D Figueroa; D MacNeil; M A Cascieri; R Nargund; R Bakshi; M Abramovitz; R Stocco; S Kargman; G O'Neill; L H Van Der Ploeg; J Evans; A A Patchett; R G Smith; A D Howard
Journal:  Science       Date:  1999-06-25       Impact factor: 47.728

7.  Characterization of agonist-induced motilin receptor trafficking and its implications for tachyphylaxis.

Authors:  Vahideh Lamian; Adam Rich; Zhengping Ma; James Li; Ramakrishna Seethala; David Gordon; Yves Dubaquie
Journal:  Mol Pharmacol       Date:  2005-10-12       Impact factor: 4.436

8.  Prokineticin-2, motilin, ghrelin and metoclopramide: prokinetic utility in mouse stomach and colon.

Authors:  Anna K Bassil; Narinder B Dass; Charles D Murray; Alison Muir; Gareth J Sanger
Journal:  Eur J Pharmacol       Date:  2005-10-19       Impact factor: 4.432

9.  An action of erythromycin in the intestine that is not mediated via motilin receptors.

Authors:  J B Furness; M J Clark; T Wright; P P Bertrand; J C Bornstein; M Verlinden
Journal:  Clin Exp Pharmacol Physiol       Date:  1999-02       Impact factor: 2.557

10.  Motilin and erythromycin-A share a common binding site in the third transmembrane segment of the motilin receptor.

Authors:  Luo Xu; Inge Depoortere; Pascale Vertongen; Magali Waelbroeck; Patrick Robberecht; Theo L Peeters
Journal:  Biochem Pharmacol       Date:  2005-09-15       Impact factor: 5.858

View more
  9 in total

1.  Upper gastrointestinal promotility drugs: not all uniform?

Authors:  Rita Brun; Braden Kuo
Journal:  Indian J Gastroenterol       Date:  2009 Jul-Aug

2.  Colitis affects the smooth muscle and neural response to motilin in the rabbit antrum.

Authors:  Inge Depoortere; Theo Thijs; Sara Janssen; Betty De Smet; Jan Tack
Journal:  Br J Pharmacol       Date:  2009-12-04       Impact factor: 8.739

3.  The antibiotic azithromycin is a motilin receptor agonist in human stomach: comparison with erythromycin.

Authors:  John Broad; Gareth J Sanger
Journal:  Br J Pharmacol       Date:  2013-04       Impact factor: 8.739

4.  Regional- and agonist-dependent facilitation of human neurogastrointestinal functions by motilin receptor agonists.

Authors:  J Broad; S Mukherjee; M Samadi; J E Martin; G E Dukes; G J Sanger
Journal:  Br J Pharmacol       Date:  2012-10       Impact factor: 8.739

Review 5.  Ghrelin and motilin receptors as drug targets for gastrointestinal disorders.

Authors:  Gareth J Sanger; John B Furness
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-09-22       Impact factor: 46.802

6.  The hungry stomach: physiology, disease, and drug development opportunities.

Authors:  Gareth J Sanger; Per M Hellström; Erik Näslund
Journal:  Front Pharmacol       Date:  2011-02-18       Impact factor: 5.810

7.  Characterization of the gastric motility response to human motilin and erythromycin in human motilin receptor-expressing transgenic mice.

Authors:  Shinichi Kato; Aoi Takahashi; Mai Shindo; Ayano Yoshida; Tomoe Kawamura; Kenjiro Matsumoto; Bunzo Matsuura
Journal:  PLoS One       Date:  2019-02-21       Impact factor: 3.240

Review 8.  Translational neuropharmacology: the use of human isolated gastrointestinal tissues.

Authors:  G J Sanger; J Broad; V Kung; C H Knowles
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

9.  Motilin: towards a new understanding of the gastrointestinal neuropharmacology and therapeutic use of motilin receptor agonists.

Authors:  G J Sanger; Y Wang; A Hobson; J Broad
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.